Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by Eoganachton Apr 05, 2022 1:39pm
374 Views
Post# 34577447

The 23 Optimized Patients

The 23 Optimized PatientsI think I finally understand the data for the optimized patients. If I got anything wrong please correct me.

In the last newsletter there were 18 patients who had received an optimized treatment.

The 90 day data for those 18 patients was as follows:

44% CR (8 patients)
11% partial response (2 patients)
39% pending (7 patients)
6% no response (1 patient) 

We were waiting to find out what happened to those 7 pending patients. Would they also be CR at 90 days? Since then 5 more patients have been treated so now there are 23 patients with an optimized treatment and since there are now 3 patients pending, 2 of the 5 reached 90 days so there are 9 more patients at the 90 day mark than there were at the time of the last newsletter. Here are the results for the 23 optimized patients.

The 90 day data for the current 23 optimized patients is as follows:

52.2%
CR (12 patients)
17.4% partial response (4 patients)
13 % pending (3 patients)
The news release does not explicitly tell us how many non-responders there were, but 23-19=4 therefore:
17% no response (4 patients)

Of the 9 patients who reached 90 days since the last report 
44%
CR (4 patients)
22% partial response (2 patients)
33% no response (3 patients)

As the news release makes explicit there is still the potential of 82.6 CR at 90 days for the 23 optimized patients (52.2% CR + 17.4% PR + 13% pending)

<< Previous
Bullboard Posts
Next >>